Dendrobium officinale leaf extract DCG17 and application thereof in skin care
By preparing Dendrobium officinale leaf extract DCG17, the problem of promoting elastin gene expression and synthesis in existing technologies has been solved, achieving the effects of combating skin aging caused by UVA, repairing skin damage and reducing scar formation, and is non-toxic to cells.
Patent Information
- Application Number
- CN202511449991.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-10-11
- Publication Date
- 2025-12-23
AI Technical Summary
Existing technologies are insufficient to effectively promote the expression and synthesis of elastin genes, making it difficult to effectively prevent and repair skin aging, skin damage, and scar formation caused by UVA.
The extract DCG17 from Dendrobium officinale leaves is prepared using a specific method and is used to prepare drugs or cosmetics that combat UVA-induced skin aging, repair skin damage, and reduce scar formation.
It significantly promotes the expression and synthesis of elastin genes, effectively combats skin aging caused by UVA, repairs skin damage, reduces scar formation, and is non-toxic to human dermal fibroblasts within a concentration range of 800 μg/mL.
Smart Images
Figure CN121177408A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of cosmetics and pharmaceutical technology, specifically relating to the field of plant-based cosmetics and pharmaceuticals, and more specifically, to DCG17, an extract of Dendrobium officinale leaves, compositions containing it, and its application in the preparation of cosmetics and pharmaceuticals. DCG17 can be used to prepare cosmetics or pharmaceuticals that combat UVA-induced skin aging, repair skin damage, reduce scar formation, and promote wound healing; it can also be used to prepare pharmaceuticals or cosmetics that promote elastin gene expression and synthesis. Background Technology
[0002] The skin is the body's main protective barrier, composed of the epidermis, dermis, and subcutaneous tissue. The dermis is mainly composed of fibroblasts and the extracellular matrix (ECM) they produce, with elastin accounting for approximately 0.6%–7.9% of the ECM [Gardeazabal L., Izeta A. Elastin and collagen fibres in cutaneous wound healing. Experimental Dermatology, 2024, 33 (3), e15052]. In ultraviolet (UV) radiation, long-wave UVA (320–400 nm) can penetrate deep into the dermis, triggering a series of pathological events, including excessive generation of reactive oxygen species (ROS), activation of matrix metalloproteinases (MMPs), and degradation of ECM components such as collagen and elastin. These processes ultimately lead to decreased skin elasticity, wrinkle formation, and impaired barrier function, necessitating effective preventative strategies [Fu B., WanY., Ma X., Chang Z., Yang X., Liu X., Wu H., Cheng S., Du M. Salmon leathercollagen peptide alleviates UVA-induced photoaging via Nrf2 / Keap1 pathway by enhancing antioxidant defense and preserving skin elasticity. FoodBioscience, 2025, 72, 107494]. Elastin is abundant in normal skin and common scars, but rarely found in hypertrophic scars or keloids [Labadie JG, Dasgeb B., Phillips TJ, Arndt K. A., What Are Scars? In Procedures in Cosmetic Dermatology: Scar Management (Second Edition), Labadie, JG; Alam, M.; Dover, JS, Eds. Elsevier:2025; pp 1-10]. The soft tissue of scars treated with pressure therapy showed significant improvement in flexibility, and the transcriptional level and expression of elastin were increased [Zhang Yixin, Chai Jun. Mechanism and clinical application of pressure therapy for scars. Chinese Journal of Burns and Wound Repair, 2025, 41 (4), 316-324].Therefore, promoting the expression of elastin genes and the synthesis of elastin is beneficial for combating skin aging caused by UVA, for repairing skin damage, and for reducing scar formation. Summary of the Invention
[0003] This invention is based on the significant activity and function of Dendrobium officinale leaf extract DCG17 in promoting elastin gene expression and elastin synthesis, and its ability to combat UVA-induced skin aging, repair skin damage, reduce scar formation, and repair wounds. The aim is to provide Dendrobium officinale leaf extract DCG17, compositions containing it, and its application in the preparation of cosmetics and pharmaceuticals. Specifically, it provides its application in the preparation of anti-skin aging drugs, drugs for reducing scar formation, and drugs for repairing skin damage and wounds. It also provides its application in the preparation of cosmetics for combating UVA-induced skin aging, cosmetics for repairing skin damage, and cosmetics for reducing scar formation and repairing wounds. A novel method for preparing Dendrobium officinale leaf extract DCG17 is also provided.
[0004] To achieve the above-mentioned objectives of the present invention, the present invention provides the following technical solution:
[0005] Dendrobium officinale leaf extract DCG17 was prepared by the following method:
[0006] The dried leaves of *Dendrobium officinale* were pulverized, and the powder was extracted once with 50% ethanol aqueous solution at 60 °C by ultrasonication for 1 h. After standing, the supernatant was filtered, and the filtrate was concentrated and evaporated to dryness using a rotary evaporator at 60 °C to obtain the crude extract. The crude extract was dissolved in water and packed into an HPD100 macroporous resin column. The sample was loaded at a flow rate of 1 column volume / h and eluted with a gradient of distilled water, 10% ethanol, 30% ethanol, and 95% ethanol. The 30% ethanol eluent was concentrated and evaporated to dryness using a rotary evaporator at 60 °C to obtain DCG16. The DCG16 sample was taken, 95% ethanol was added, and the mixture was ultrasonicated at 60 °C for 30 min. After filtration, the filtrate was concentrated and evaporated to dryness using a rotary evaporator at 60 °C to obtain DCG17.
[0007] A method for preparing DCG17, an extract from Dendrobium officinale leaves, comprising the following steps:
[0008] The dried leaves of *Dendrobium officinale* were pulverized, and the powder was extracted once with 50% ethanol aqueous solution at 60 °C by ultrasonication for 1 h. After standing, the supernatant was filtered, and the filtrate was concentrated and evaporated to dryness using a rotary evaporator at 60 °C to obtain the crude extract. The crude extract was dissolved in water and packed into an HPD100 macroporous resin column. The sample was loaded at a flow rate of 1 column volume / h and eluted with a gradient of distilled water, 10% ethanol, 30% ethanol, and 95% ethanol. The 30% ethanol eluent was concentrated and evaporated to dryness using a rotary evaporator at 60 °C to obtain DCG16. The DCG16 sample was taken, 95% ethanol was added, and the mixture was ultrasonicated at 60 °C for 30 min. After filtration, the filtrate was concentrated and evaporated to dryness using a rotary evaporator at 60 °C to obtain DCG17.
[0009] The application of the Dendrobium officinale leaf extract DCG17 in the preparation of drugs for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.
[0010] The pharmaceutical composition comprises the aforementioned Dendrobium officinale leaf extract DCG17 and a pharmaceutically acceptable carrier.
[0011] The pharmaceutical composition is used in the preparation of drugs for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.
[0012] The method for preparing the pharmaceutical composition includes the following steps: first, obtaining Dendrobium officinale leaf extract DCG17 by the method for preparing DCG17, and then adding a pharmaceutically acceptable carrier.
[0013] The cosmetic uses the aforementioned Dendrobium officinale leaf extract DCG17 as the active ingredient, along with conventional cosmetic excipients.
[0014] The application of the Dendrobium officinale leaf extract DCG17 in the preparation of cosmetics for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.
[0015] The method for preparing the cosmetic is characterized by comprising the following steps: first, obtaining Dendrobium officinale leaf extract DCG17 by the method for preparing DCG17, and then adding commonly used cosmetic excipients.
[0016] Application of Dendrobium officinale leaf extract DCG17 in the preparation of drugs or cosmetics that promote elastin gene expression and synthesis.
[0017] The application of the Dendrobium officinale leaf extract DCG17 in the preparation of drugs or cosmetics for wound repair.
[0018] In this invention, when the extract DCG17 or its composition is used to prepare a drug, the content of the extract or its composition in the drug is preferably 0.1% to 99%; in the drug composition, the content of any one or any combination of the active ingredient extracts is preferably 0.5% to 90%. The drug composition of this invention is preferably used in the form of a dose per unit body weight. In this invention, the prepared drug is preferably administered orally. The drug preparations include topical ointments, tablets, capsules, pills, drops, etc., including but not limited to the above-mentioned preparations.
[0019] In this invention, when the extract DCG17 is used to prepare cosmetics, the formulation of the cosmetics is not limited and can be prepared using conventional cosmetic preparation methods.
[0020] Compared with the prior art, the present invention has the following advantages:
[0021] 1. The Dendrobium officinale leaf extract DCG17 can significantly promote the expression of elastin gene in human dermal fibroblasts under UVA radiation.
[0022] 2. The Dendrobium officinale leaf extract DCG17 showed no toxicity to human dermal fibroblasts at a concentration range of 800 μg / mL.
[0023] 3. The Dendrobium officinale leaf extract DCG17 exhibits significant activity in promoting elastin gene expression and elastin synthesis, and can be used in the preparation of drugs or cosmetics that promote elastin gene expression and synthesis. It also possesses pharmacological effects and functions such as combating UVA-induced skin aging, repairing skin damage, reducing scar formation, and repairing wounds. It can be used to prepare drugs or cosmetics with similar functions and effects. Attached Figure Description
[0024] Figure 1 DCG17 did not show significant cytotoxicity against human dermal fibroblasts at a concentration range of 800 μg / mL. Detailed Implementation
[0025] The following description, in conjunction with the accompanying drawings, uses embodiments of the present invention to further illustrate the substantive content of the invention, but does not limit the invention thereto.
[0026] Example 1
[0027] Preparation of DCG17, a leaf extract of Dendrobium officinale Kimura & Migo:
[0028] The dried Dendrobium officinale leaves were crushed, and 1.4 kg of powder was taken and extracted once by ultrasonic extraction with 10 L of 50% ethanol aqueous solution at 60 °C (1 h). After standing, the supernatant was filtered, and the filtrate was concentrated and evaporated to dryness by rotary evaporator at 60 °C to obtain crude extract (0.3 kg).
[0029] 40 g of crude extract was dissolved in 300 mL of water and packed into an HPD100 macroporous resin column at a flow rate of 1 column volume (BV) / h. Gradient elution was performed with distilled water (3 BV), 10% ethanol (3 BV), 30% ethanol (3 BV), and 95% ethanol (3 BV), respectively. The 30% ethanol eluent was concentrated to dryness using a rotary evaporator at 60 °C to obtain DCG16 (4.2 g).
[0030] Take 1 g of DCG16 sample, add 20 mL of 95% ethanol, sonicate at 60 °C for 30 min, filter, and concentrate the filtrate to dryness using a rotary evaporator at 60 °C to obtain DCG17 (196.9 mg).
[0031] Example 2
[0032] Activity assay of DCG17 in Dendrobium officinale leaf extract:
[0033] 1. Cell
[0034] The cells used in this test were human dermal fibroblasts, batch number: Fb230131, provided by Guangdong Boxi Shaanxi Branch.
[0035] 2. Main reagents
[0036] DMEM culture medium (Gibco), fetal bovine serum (Lanzhou Rongye), PBS (Solepro), MTT (Sigma), DMSO (Sigma), AG RNAex Pro Reagent (Aikerui Biotechnology), reverse transcription kit (Aikerui Biotechnology), fluorescent dye (Aikerui Biotechnology), TGF-β1 (Peprotech).
[0037] 3. Main Equipment
[0038] CO2 incubator (Thermo, 150I), ultra-clean workbench (Sujing Antai, SW-CJ-2F), microplate reader (BioTek, Epoch), UVA irradiator (Philips), inverted microscope (Olympus, CKX53), and real-time PCR instrument (Roche, Lightcycler 480 II).
[0039] 4. Cytotoxicity assay based on human dermal fibroblasts
[0040] 4.1 Cell viability testing methods
[0041] 1) Cell seeding: After cell resuscitation, when the cell plating rate reaches about 50%~60%, seed the cells into 96-well plates and incubate overnight in a CO2 incubator (37 °C, 5% CO2).
[0042] 2) Experimental Groups: The experiment included a zeroing group, a solvent control group, a positive control group, and a sample group. In the sample group, each sample had 8 concentration gradients, and each concentration gradient had 3 replicate wells.
[0043] 3) Solution preparation: Prepare working solutions of the DCG17 sample to be tested with concentrations of 6.25 μg / mL, 12.5 μg / mL, 25 μg / mL, 50 μg / mL, 100 μg / mL, 200 μg / mL, 400 μg / mL and 800 μg / mL.
[0044] 4) Drug administration: Drug administration was performed when the cell seeding rate in the 96-well plate reached 50%–60%. For the solvent control group, 200 μL of culture medium was added to each well; for the positive control group, 200 μL of culture medium containing 10% DMSO was added to each well; for the sample group, 200 μL of culture medium containing the corresponding concentration of the sample was added to each well; for the zeroing group, no cells were seeded, only 200 μL of cell culture medium was added. After drug administration, the 96-well plate was placed in a CO2 incubator (37 ℃, 5% CO2) and incubated for 24 h.
[0045] 5) Detection: After culturing cells for 24 h, discard the supernatant, add MTT working solution (0.5 mg / mL), and incubate at 37 ℃ in the dark for 4 h. After incubation, discard the supernatant, add 150 μL DMSO to each well, and read the OD value at 490 nm.
[0046] 6) Calculation of relative cell viability: According to the formula, relative cell viability (%) = [(sample well OD − zeroing well OD) / (solvent control well OD − zeroing well OD)] × 100%.
[0047] 4.2 Cell morphology testing methods
[0048] 1) Cell seeding: After cell resuscitation, when the cell seeding rate reaches about 50%~60%, seed the cells into 24-well plates and incubate overnight in a CO2 incubator (37 °C, 5% CO2).
[0049] 2) Experimental Groups: The experiment included a solvent control group and a sample group. Within the sample group, five concentration gradients were set up (50 μg / mL, 100 μg / mL, 200 μg / mL, 400 μg / mL, and 800 μg / mL).
[0050] 3) Drug administration: Drug administration was performed when the cell deposition rate in the 24-well plate reached 50%–60%. 1 mL of culture medium was added to each well of the solvent control group; 1 mL of culture medium containing the corresponding concentration of the test sample was added to each well of the sample group. After drug administration, the 24-well plate was placed in a CO2 incubator (37 °C, 5% CO2) and incubated for 24 h.
[0051] 4) Take photos: After incubation, discard the supernatant and take photos under an inverted microscope.
[0052] 4.3 Test Results
[0053] Based on MTT (Table 1) and morphological results ( Figure 1 Based on human fibroblasts, DCG17 did not show significant cytotoxicity at concentrations in the range of 800 μg / mL.
[0054] Table 1. MTT assay results of sample DCG17 on human dermal fibroblasts
[0055] sample concentration Cell viability (%) DCG17 6.25 μg / mL 107.77 ± 3.42 DCG17 12.5 μg / mL 104.95 ± 2.99 DCG17 25 μg / mL 103.86 ± 1.61 DCG17 50 μg / mL 98.58 ± 2.76 DCG17 100 μg / mL 98.03 ± 4.80 DCG17 200 μg / mL 97.65 ± 2.64 DCG17 400 μg / mL 96.99 ± 2.97 DCG17 800 μg / mL 94.96 ± 3.73 DMSO (positive control) 10% 16.18 ± 2.64 negative control - 100.00 ± 1.40
[0056] 5. Gene expression level assay based on fibroblasts
[0057] 5.1 Test Method
[0058] 1) Cell seeding: After cell resuscitation, when the cell plating rate reaches about 60%, seed the cells into 6-well plates and incubate overnight in a CO2 incubator (37 °C, 5% CO2).
[0059] 2) Solution preparation: Prepare working solutions for the test substances according to the test groups.
[0060] 3) Drug administration: According to the test groups, when the cell deposition rate in the 6-well plate reached 30%~50%, drug administration was performed in groups, with 3 replicates per group. 2 mL of culture medium was added to each well of the blank control group and negative control group, 2 mL of culture medium containing the corresponding concentration of TGF-β1 was added to each well of the positive control group, and 2 mL of culture medium containing the corresponding concentration of the test sample was added to each well of the sample group. After drug administration, the 6-well plate was incubated in a CO2 incubator (37 °C, 5% CO2) for 24 h.
[0061] 4) UVA irradiation: According to the test grouping, all groups except the blank control group were subjected to UVA irradiation with an irradiation dose of 30 J / cm². 2 After irradiation, the samples were placed in an incubator (37 °C, 5% CO2) and cultured for another 24 h.
[0062] 5) Cell collection: After incubation, aspirate the old solution, wash twice with PBS, add 1 mL of AG RNAex ProReagent to each well, lyse the cells by pipetting, and collect the sample.
[0063] 6) Gene expression detection: RNA was extracted, reverse transcribed into cDNA, and then detected by real-time quantitative PCR using 2... -△△CT The method is used to calculate the results.
[0064] 7) Calculation of upward adjustment rate:
[0065] Upregulation rate (%) = [(Sample group − Blank control group) / Blank control group] × 100%
[0066] 8) Statistical Analysis of Results: GraphPad Prism Program software was used for plotting, and the results are expressed as Mean ± SD. t-tests were used for comparisons between groups. All statistical analyses were two-tailed. P < 0.05 was considered statistically significant, and P < 0.01 was considered highly statistically significant.
[0067] 5.2 Results of Elastin Gene Expression Test
[0068] The test results are shown in Table 2. Compared with the blank control (BC) group, the expression level of Elastin gene in the negative control (NC) group was significantly downregulated, indicating that the stimulation conditions of this test were effective. Compared with the NC group, the expression level of Elastin gene in the positive control (PC) group was significantly upregulated, indicating that the positive control of this test was effective. Compared with the NC group, the expression level of Elastin gene in sample DCG17 (100 μg / mL) was significantly upregulated, with an upregulation rate of 33.33%.
[0069] Table 2. Results of Elastin gene detection
[0070] Group Mean expression level SD P-value Upward adjustment rate (vs NC) BC 1.00 0.12 - - NC 0.72 0.06 <![CDATA[0.019 # ]]> - PC 2.95 0.28 0.000** 309.72% DCG17 (100 μg / mL) 0.96 0.12 0.035* 33.33%
[0071] Note: Use 2 -△△CT When calculating the results using the method and performing statistical analysis using the t-test, the significance level compared to the BC group was [missing information]. # This means that P < 0.05 indicates that... # P < 0.01 indicates that ## Compared with the NC group, significance is indicated by *, P < 0.05 is indicated by *, and P < 0.01 is indicated by **.
[0072] Example 3:
[0073] Cream formulation containing Dendrobium officinale leaf extract DCG17 (W%):
[0074] Dendrobium officinale leaf extract DCG17 0.03
[0075] Stearic acid 8.0
[0076] C16 alcohol 2.0
[0077] Self-emulsifying monoglyceride 2.0
[0078] Hydrogenated lanolin 2.0
[0079] Liquid paraffin 12.0
[0080] Glycerin 7.0
[0081] Emulsifier 1.5
[0082] Preservative 0.2
[0083] Fragrance 0.2
[0084] Add deionized water to 100
[0085] The cosmetic product of the above-described formula of the present invention is prepared using conventional methods for manufacturing cosmetics.
[0086] Example 4:
[0087] Emulsion formulation containing Dendrobium officinale leaf extract DCG17 (W%):
[0088] Dendrobium officinale leaf extract DCG17 0.03
[0089] Stearic acid 1.4
[0090] Cetyl alcohol 0.1
[0091] 2-Ethyl alcohol cetyl stearate 1.8
[0092] Isopropyl myristate 0.2
[0093] 2-Hexyl-1-decyl alcohol 1.0
[0094] Liquid paraffin 7.5
[0095] Glycerin 3.0
[0096] Propylene glycol 8.0
[0097] Triethanolamine 1.0
[0098] Carboxyvinyl polymer 0.35
[0099] Arlacel 165 2.0
[0100] Preservative 0.2
[0101] Fragrance 0.2
[0102] Add deionized water to 100
[0103] The cosmetic product of the above-described formula of the present invention is prepared using conventional methods for manufacturing cosmetics.
[0104] Example 5
[0105] Facial cleanser containing Dendrobium officinale leaf extract DCG17.
[0106] 1. Materials
[0107] The Dendrobium officinale leaf extract DCG17 obtained by the same method as in Example 1 uses cosmetic-grade or food-grade raw materials.
[0108] 2. Formula
[0109] Dendrobium officinale leaf extract DCG17 0.5 g, glycerin 3.0 g, butylene glycol 3.0 g, propylene glycol 0.6 g, sodium EDTA 0.1 g, guar gum 0.3 g, zinc dioxide 2.0 g, C12-15 benzoate 4.0 g, C12-20 alkyl glucoside 3.0 g, C14-22 alcohol 0.5 g, cetearyl alcohol 1.2 g, parabens 0.2 g, sodium stearate 0.3 g, polydimethylsiloxane alcohol 0.5 g, polysorbate 0.2 g, deionized water 60 g.
[0110] 3. Preparation process
[0111] Weigh out the prescribed amount of Dendrobium officinale leaf extract DCG17 and dissolve it completely in purified water. Take glycerin, butylene glycol, propylene glycol, sodium EDTA, guar gum, zinc dioxide, sodium stearate, C12-15 benzoate, C12-20 alkyl glucoside, C14-22 alcohol, and cetearyl alcohol, and mix them with purified water. Take parabens, polydimethylsiloxane alcohol, and polysorbate, and mix them with purified water. Combine the prepared solutions, stir thoroughly, and bottle to obtain the final product.
[0112] Example 6:
[0113] Add the excipient to the Dendrobium officinale leaf extract DCG17 at a weight ratio of 1:1 or 1:2, then granulate and compress into tablets.
[0114] Example 7:
[0115] Tablets: Dendrobium officinale leaf extract DCG17 10mg, lactose 180mg, starch 55mg, magnesium stearate 5mg; Preparation method: Mix Dendrobium officinale leaf extract DCG17, lactose and starch, moisten evenly with water, sieve and dry the moistened mixture, sieve again, add magnesium stearate, and then compress the mixture into tablets, each weighing 250 mg, with a compound content of 10 mg.
[0116] Example 8:
[0117] The extract DCG17 from Dendrobium officinale leaves was prepared into capsules using conventional capsule formulation methods.
[0118] Example 9:
[0119] Capsules: Dendrobium officinale leaf extract DCG17 10 mg, lactose 187 mg, magnesium stearate 3 mg;
[0120] Preparation method: Mix Dendrobium officinale leaf extract DCG17 with adjuvants, sieve, mix evenly, and fill the resulting mixture into hard gelatin capsules, each capsule weighing 200 mg and containing 10 mg of active ingredient.
[0121] Example 10:
[0122] Topical ointment: Melt the base ingredients (such as beeswax and coconut oil) by heating in a water bath, add Dendrobium officinale leaf extract DCG17 and stir well. After cooling, put it into a sterilized sealed container and refrigerate.
Claims
1. Dendrobium officinale leaf extract DCG17, characterized in that: It is prepared by the following method: The dried leaves of *Dendrobium officinale* were pulverized, and the powder was extracted once with 50% ethanol aqueous solution at 60 °C by ultrasonication for 1 h. After standing, the supernatant was filtered, and the filtrate was concentrated and evaporated to dryness using a rotary evaporator at 60 °C to obtain the crude extract. The crude extract was dissolved in water and packed into an HPD100 macroporous resin column. The sample was loaded at a flow rate of 1 column volume / h and eluted with a gradient of distilled water, 10% ethanol, 30% ethanol, and 95% ethanol. The 30% ethanol eluent was concentrated and evaporated to dryness using a rotary evaporator at 60 °C to obtain DCG16. The DCG16 sample was taken, 95% ethanol was added, and the mixture was ultrasonicated at 60 °C for 30 min. After filtration, the filtrate was concentrated and evaporated to dryness using a rotary evaporator at 60 °C to obtain DCG17.
2. A method for preparing DCG17, an extract of Dendrobium officinale leaves, characterized in that, The method includes the following steps: The dried leaves of *Dendrobium officinale* were pulverized, and the powder was extracted once with 50% ethanol aqueous solution at 60 °C by ultrasonication for 1 h. After standing, the supernatant was filtered, and the filtrate was concentrated and evaporated to dryness using a rotary evaporator at 60 °C to obtain the crude extract. The crude extract was dissolved in water and packed into an HPD100 macroporous resin column. The sample was loaded at a flow rate of 1 column volume / h and eluted with a gradient of distilled water, 10% ethanol, 30% ethanol, and 95% ethanol. The 30% ethanol eluent was concentrated and evaporated to dryness using a rotary evaporator at 60 °C to obtain DCG16. The DCG16 sample was taken, 95% ethanol was added, and the mixture was ultrasonicated at 60 °C for 30 min. After filtration, the filtrate was concentrated and evaporated to dryness using a rotary evaporator at 60 °C to obtain DCG17.
3. The use of the Dendrobium officinale leaf extract DCG17 as described in claim 1 in the preparation of a drug for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.
4. A pharmaceutical composition comprising the Dendrobium officinale leaf extract DCG17 as described in claim 1 and a pharmaceutically acceptable carrier.
5. The use of the pharmaceutical composition of claim 4 in the preparation of a medicament for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.
6. The method for preparing the pharmaceutical composition according to claim 4, characterized in that, The method includes the following steps: first, obtaining Dendrobium officinale leaf extract DCG17 by the preparation method described in claim 2, and then adding a pharmaceutically acceptable carrier.
7. A cosmetic product, comprising the Dendrobium officinale leaf extract DCG17 as described in claim 1 as an active ingredient, plus conventional cosmetic excipients.
8. The application of the Dendrobium officinale leaf extract DCG17 as described in claim 1 in the preparation of cosmetics for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.
9. The use of the Dendrobium officinale leaf extract DCG17 as described in claim 1 in the preparation of drugs or cosmetics for wound repair.
10. The use of the Dendrobium officinale leaf extract DCG17 according to claim 1 in the preparation of drugs or cosmetics that promote elastin gene expression and synthesis.